Epigenetic control of IL-23 expression in keratinocytes is important for chronic skin inflammation

Li, Hui; Yao, Qi; Mariscal, Alberto Garcia; Wu, Xudong; Hülse, Justus; Pedersen, Esben; Helin, Kristian; Waisman, Ari; Vinkel, Caroline; Thomsen, Simon Francis; Avgustinova, Alexandra; Benitah, Salvador Aznar; Lovato, Paola; Norsgaard, Hanne; Mortensen, Mette Sidsel; Veng, Lone; Rozell, Björn; Brakebusch, Cord

doi:10.1038/s41467-018-03704-z

Cited by 109 publications

(88 citation statements)

References 35 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Keratinocyte‐derived IL‐23 has been shown to be sufficient to mediate skin inflammation in murine models . In a murine model of selective loss of IL‐23 in keratinocytes, skin inflammation was reduced, suggesting that epithelial cells may also serve as an additional source of IL‐23 in inflammation .…”

Section: The Concept Of Il‐23–independent Il‐17 Productionmentioning

confidence: 99%

“…126 Keratinocyte-derived IL-23 has been shown to be sufficient to mediate skin inflammation in murine models. 127 In a murine model of selective loss of IL-23 in keratinocytes, skin inflammation was reduced, suggesting that epithelial cells may also serve as an additional source of IL-23 in inflammation. 127 IL-23 secreted by bronchial epithelial cells has also been documented to contribute to allergic sensitization in a murine model.…”

Section: Myeloid Cells As Producers Of Il-23 In Manmentioning

confidence: 99%

“…127 In a murine model of selective loss of IL-23 in keratinocytes, skin inflammation was reduced, suggesting that epithelial cells may also serve as an additional source of IL-23 in inflammation. 127 IL-23 secreted by bronchial epithelial cells has also been documented to contribute to allergic sensitization in a murine model. 128 Despite these models, the literature strongly supports myeloid cells as being the chief orchestrators of IL-23-mediated disease.…”

Section: Myeloid Cells As Producers Of Il-23 In Manmentioning

confidence: 99%

See 2 more Smart Citations

Interleukin‐23 pathway at the enthesis: The emerging story of enthesitis in spondyloarthropathy

Bridgewood

Sharif

Sherlock

et al. 2020

Immunological Reviews

View full text Add to dashboard Cite

The inflammatory disorders collectively termed the seronegative spondyloarthropathies (SpA) include ankylosing spondylitis (AS), psoriatic arthritis (PsA), reactive arthritis, the arthritis associated with inflammatory bowel disease including Crohn's disease and ulcerative colitis, the arthritis related to anterior uveitis, and finally, somewhat controversially Behcet's disease. All of these diseases are associated with SNPs in the IL‐23R or the interleukin‐23 (IL‐23) cytokine itself and related downstream signaling JAK pathway genes and the interleukin‐17 (IL‐17) pathway. In rheumatoid arthritis, the target of the immune response is the synovium but the SpA disorders target the tendon, ligament, and joint capsule skeletal anchorage points that are termed entheses. The discovery that IL‐23R–expressing cells were ensconced in healthy murine enthesis, and other extraskeletal anchorage points including the aortic root and the ciliary body of the eye and that systemic overexpression of IL‐23 resulted in a severe experimental SpA, confirmed a fundamentally different immunobiology to rheumatoid arthritis. Recently, IL‐23R–expressing myeloid cells and various innate and adaptive T cells that produce IL‐17 family cytokines have also been described in the human enthesis. Blockade of IL‐23 pathway with either anti‐p40 or anti‐p19 subunits has resulted in some spectacular therapeutic successes in psoriasis and PsA including improvement in enthesitis in the peripheral skeleton but has failed to demonstrate efficacy in AS that is largely a spinal polyenthesitis. Herein, we discuss the known biology of IL‐23 at the human enthesis and highlight the remarkable emerging story of this unique skeletal tissue.

show abstract

Section: The Concept Of Il‐23–independent Il‐17 Productionmentioning

confidence: 99%

Section: Myeloid Cells As Producers Of Il-23 In Manmentioning

confidence: 99%

Section: Myeloid Cells As Producers Of Il-23 In Manmentioning

confidence: 99%

See 1 more Smart Citation

Interleukin‐23 pathway at the enthesis: The emerging story of enthesitis in spondyloarthropathy

Bridgewood

Sharif

Sherlock

et al. 2020

Immunological Reviews

View full text Add to dashboard Cite

show abstract

“…A recent study by Li et al demonstrate that epigenetic regulation of keratinocytes can contribute to chronic skin inflammation [34]. Actin polymerizing molecule N-WASP is capable of modulating interleukin IL-23 expression in keratinocytes by regulating the degradation of the histone methyltransferases G9a and GLP, as well as H3K9 dimethylation level of the IL-23 promoter.…”

Section: Pro-inflammatory Phenotype and Epigenetic Regulationmentioning

confidence: 99%

“…Actin polymerizing molecule N-WASP is capable of modulating interleukin IL-23 expression in keratinocytes by regulating the degradation of the histone methyltransferases G9a and GLP, as well as H3K9 dimethylation level of the IL-23 promoter. This mechanism mediates the induction of IL-23 by tumor necrosis factor (TNF-α), a known inducer of IL-23 in psoriasis [34]. …”

Section: Pro-inflammatory Phenotype and Epigenetic Regulationmentioning

confidence: 99%

The Emerging Spectrum of Early Life Exposure-Related Inflammation and Epigenetic Therapy

Yang

Ali

Andaloussi

et al. 2018

Cancer Stud Mol Med Open J

View full text Add to dashboard Cite

Early life exposure to a variety of insults during sensitive windows of development can reprogram normal physiological responses and alter disease susceptibility later in life. During this process, Inflammation triggered by a variety of adverse exposures plays an important role in the initiation and development of many types of diseases including tumorigenesis. This review article summaries the current knowledge about the role and mechanism of inflammation in development of diseases. In addition, epigenome alteration related to inflammation and treatment options using epigenetic modifiers are highlighted and discussed.

show abstract

Fluorescence Turn‐off Magnetic Fluorinated Graphene Composite with High NIR Absorption for Targeted Drug Delivery

et al. 2020

Self Cite

View full text Add to dashboard Cite

Although fluorinated graphene/Fe3O4 composites exhibit a unique structure and chemical surface, and thus hold great potential in many fields, their effective synthesis has remained a headache because of poor dispersity and easy aggregation behavior. Herein, we report a novel method to prepare hyaluronic acid (HA)‐modified fluorinated graphene with a well‐defined structure and good solubility in various media, and this then allowed us for the first time to controllably deposit magnetic Fe3O4 nanoparticles onto the sheets with designed ratio and contents. This strategy further guaranteed a multifunctional composite that possessed HA and magnetism‐induced dual‐targeting effect towards cancer cells and high near‐infrared absorption for photothermal therapy (PTT). Moreover, this composite also showed an effective turn‐off fluorescence effect for the anticancer drug doxorubicin, allowing us to visually monitor the drug loading procedure. Anticancer experiments indicated that such a successful combination of PTT and chemotherapy with special selectivity toward cancer cells exhibited a much better therapeutic effect than single therapy.

show abstract

Epigenetic control of IL-23 expression in keratinocytes is important for chronic skin inflammation

Cited by 109 publications

References 35 publications

Interleukin‐23 pathway at the enthesis: The emerging story of enthesitis in spondyloarthropathy

Interleukin‐23 pathway at the enthesis: The emerging story of enthesitis in spondyloarthropathy

The Emerging Spectrum of Early Life Exposure-Related Inflammation and Epigenetic Therapy

Fluorescence Turn‐off Magnetic Fluorinated Graphene Composite with High NIR Absorption for Targeted Drug Delivery

Contact Info

Product

Resources

About